Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

GVAX cancer vaccines highlighted at the ASGT meeting

June 12, 2002

ING-1 suitable for further evaluation according to initial human study

June 7, 2002

Promising phase I results with ISF-154 lead to initiation of phase II trial in CLL

June 7, 2002

Virulizin granted fast track designation in pancreatic cancer

June 6, 2002

Weekly administration of WX-G250 is safe and effective against renal cell carcinoma

June 5, 2002

MDX-010 induces tumor reductions in phase I trials in metastatic melanoma and prostate cancer

June 5, 2002

Delay in PSA and clinical progression of prostate cancer achieved using Prostvac

June 3, 2002

Final analysis of phase III data for Zamyl in AML

June 3, 2002

Second phase II trial for GVAX pancreatic cancer vaccine

May 31, 2002

Clinical data on one of Igeneon's cancer vaccine candidates discussed at ASCO meeting

May 31, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...